Patents by Inventor Eric Yi-Chun Huang

Eric Yi-Chun Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid vaccines
    Patent number: 12329812
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Grant
    Filed: August 12, 2024
    Date of Patent: June 17, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF
    Publication number: 20250170235
    Abstract: The disclosure features isolated mRNAs encoding a polypeptide that enhances immune responses to an antigen(s) of interest, such as polypeptides that activate Type I interferon pathway signaling or NFkB signaling, including mRNAs comprising one or more modified nucleobase. The disclosure also features methods of using the same, for example, for enhancing immune responses when administered with an antigen(s) of interest, such as to stimulate anti-cancer immune responses or anti-pathogen immune responses.
    Type: Application
    Filed: June 27, 2024
    Publication date: May 29, 2025
    Inventors: Eric Yi-Chun HUANG, Sze-Wah TSE, Jared IACOVELLI, Kristine MCKINNEY, Kristen HOPSON
  • CONCATEMERIC PEPTIDE EPITOPE RNAS
    Publication number: 20250135010
    Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
    Type: Application
    Filed: November 13, 2024
    Publication date: May 1, 2025
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Eric YI-CHUN HUANG, Nicholas VALIANTE, Tal ZAKS
  • Nucleic acid vaccines
    Patent number: 12274743
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Grant
    Filed: August 12, 2024
    Date of Patent: April 15, 2025
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • POLYNUCLEOTIDES ENCODING INTEGRIN BETA-6 AND METHODS OF USE THEREOF
    Publication number: 20250041393
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions ITB6 molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding ITB6 polypeptides. The LNP compositions of the present disclosure can reprogram dendritic cells, suppress T cells and/or induce immune tolerance in vivo.
    Type: Application
    Filed: November 1, 2022
    Publication date: February 6, 2025
    Inventors: Eric Yi-Chun Huang, Paul Stein, Laurie Kenney, Michelle Dutra, Myoungjoo Kim, Pranitha Vangala
  • NUCLEIC ACID VACCINES
    Publication number: 20240408191
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: August 12, 2024
    Publication date: December 12, 2024
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
  • NUCLEIC ACID VACCINES
    Publication number: 20240398931
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: August 12, 2024
    Publication date: December 5, 2024
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
  • NUCLEIC ACID VACCINES
    Publication number: 20240398927
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: February 28, 2022
    Publication date: December 5, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • MRNAS ENCODING CHIMERIC METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF
    Publication number: 20240401006
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising metabolic reprogramming molecules and membrane anchoring moieties and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding metabolic reprogramming polypeptides, e.g., IDO or TDO and membrane anchoring moieties. The LNP compositions of the present disclosure can reprogram myeloid and/or dendritic cells, suppress T cells and/or induce immune tolerance in vivo.
    Type: Application
    Filed: August 4, 2022
    Publication date: December 5, 2024
    Inventors: Laurie Kenney, Eric Yi-Chun Huang, Paul Stein, Michelle Dutra, Seymour de Picciotto, Susamma Canali, Sze-Wah Tse, Jared Iacovelli
  • NUCLEIC ACID VACCINES
    Publication number: 20240390480
    Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.
    Type: Application
    Filed: August 12, 2024
    Publication date: November 28, 2024
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe CIARAMELLA, Axel BOUCHON, Eric YI-CHUN HUANG
  • Concatemeric peptide epitope RNAs
    Patent number: 12150980
    Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 26, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Nicholas Valiante, Tal Zaks
  • TROPICAL DISEASE VACCINES
    Publication number: 20240366745
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Application
    Filed: April 15, 2024
    Publication date: November 7, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
  • MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF
    Publication number: 20240158458
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising immune modulating polypeptides and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune modulating polypeptides, e.g., interleukin 2 (IL-2) and/or granulocyte macrophage colony stimulating factor (GM-CSF). The LNP compositions of the present disclosure can stimulate T regulatory cells, e.g., increase the level and/or activity of T regulatory cells in vivo or ex vivo.
    Type: Application
    Filed: October 15, 2020
    Publication date: May 16, 2024
    Inventors: Eric Yi-Chun Huang, Jared Iacovelli, Seymour De Picciotto, Sze-Wah Tse, Laurie Kenney
  • MRNAS ENCODING GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR FOR TREATING PARKINSON'S DISEASE
    Publication number: 20240123034
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 18, 2024
    Inventors: Eric Yi-Chun Huang, Jared Iacovelli, Seymour De Picciotto, Sze-Wah Tse, Laurie Kenney, Katherine Olson, Howard Gendelman, Lee R. Mosley
  • BROAD SPECTRUM INFLUENZA VIRUS VACCINE
    Publication number: 20230310576
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: November 14, 2022
    Publication date: October 5, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
  • MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF
    Publication number: 20230130155
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising metabolic reprogramming molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding metabolic reprogramming polypeptides, e.g., IDO, TDO, AMPK, AhR, ALDH1A2, HMOX1, CD73 or CD39. The LNP compositions of the present disclosure can reprogram myeloid and/or dendritic cells, suppress T cells and/or induce immune tolerance in vivo.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 27, 2023
    Inventors: Eric Yi-Chun Huang, Sze-Wah Tse, Seymour De Picciotto, Laurie Kenney
  • METHODS OF MAKING TOLEROGENIC DENDRITIC CELLS
    Publication number: 20230112857
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising immune checkpoint inhibitor molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune checkpoint inhibitor polypeptides, e.g., PD-L1, PD-L2, B7-H3, B7-H4, CD200 Galectin 9 and CTLA4. The LNP compositions of the present disclosure can reprogram dendritic cells, suppress T cells and/or induce immune tolerance in vivo.
    Type: Application
    Filed: January 8, 2021
    Publication date: April 13, 2023
    Inventors: Eric Yi-Chun Huang, Sze-Wah Tse, Seymour De Picciotto
  • Long-lived polynucleotide molecules
    Patent number: 11603399
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: March 14, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty, Sayda M. Elbashir
  • Broad spectrum influenza virus vaccine
    Patent number: 11576961
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: February 14, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
  • INFECTIOUS DISEASE VACCINES
    Publication number: 20230020362
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: May 5, 2022
    Publication date: January 19, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir